DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

KalVista Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

88 Comunicados de prensa

Ver todos los comunicados de prensa
08/04/2026
Eventos
Web y redes sociales
Biotecnología
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/04/2026
Mercado de valores
Finanzas
Salud
Biotecnología
Ciencia
Farmacéutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
30/03/2026
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/03/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/03/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/03/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/03/2026
Mercado de valores
Finanzas
Salud
Biotecnología
Ciencia
Farmacéutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/03/2026
Eventos
Industria
Salud
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/02/2026
Eventos
Web y redes sociales
Biotecnología
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0